Physician profile
Cathleen B Varley
NPI 1134169576
$13,346.24
in general payments reported to CMS, 2019-2025
24 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what 96% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,502 · 2022: $1,656 · 2023: $1,928 · 2024: $7,075 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,842 · Consulting Fee: $4,242 · Travel and Lodging: $1,085 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,841.52 |
| Consulting Fee | $4,242.00 |
| Travel and Lodging | $1,085.32 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $4,162.62 | 2022-2025 | Verquvo |
| Abbott Laboratories | $3,166.08 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Bayer Healthcare Pharmaceuticals INC. | $1,261.62 | 2023-2024 | |
| Novo Nordisk INC | $694.16 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $605.50 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $551.69 | 2022-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $478.91 | 2021-2025 | Wainua, Farxiga, Lokelma |
| Boston Scientific Corporation | $435.24 | 2021-2025 | S-Icd System Magnet, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Scpharmaceuticals INC. | $406.12 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $293.95 | 2022-2025 | Camzyos |
| Alnylam Pharmaceuticals INC. | $228.14 | 2022-2025 | Onpattro |
| Pfizer INC. | $208.82 | 2022-2023 | |
| Esperion Therapeutics, INC. | $190.24 | 2021 | |
| Amgen INC. | $161.33 | 2021-2024 | Repatha |
| Baxter Healthcare | $137.57 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cmp Pharma, INC. | $133.96 | 2022-2023 | Carospir, Norliqva |
| Daiichi Sankyo INC. | $45.01 | 2022-2023 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $42.38 | 2023 | Inpefa |
| Kestra Medical Technology Services, INC. | $39.01 | 2025 | Assure Wcd |
| Akcea Therapeutics, INC. | $28.32 | 2021 | |
| Lilly USA, LLC | $20.30 | 2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $20.30 | 2022 | |
| Abiomed | $17.91 | 2022 | |
| Philips North America LLC | $17.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathleen Varley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.